KalVista Pharmaceuticals, Inc. (KALV)

USD 8.46

(-2.2%)

Market Cap (In USD)

418.07 Million

Revenue (In USD)

-

Net Income (In USD)

-126.64 Million

Avg. Volume

365.87 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
8.25-16.88
PE
-
EPS
-
Beta Value
0.913
ISIN
US4834971032
CUSIP
483497103
CIK
1348911
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Benjamin L. Palleiko
Employee Count
-
Website
https://www.kalvista.com
Ipo Date
2015-04-09
Details
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.